Comparative Pharmacology
Head-to-head clinical analysis: BUDESONIDE versus BUDESONIDE INHALED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUDESONIDE versus BUDESONIDE INHALED.
BUDESONIDE vs Budesonide (Inhaled)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Budesonide is a corticosteroid with potent glucocorticoid activity. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting pro-inflammatory cytokines and leukocyte migration.
Budesonide is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and chemokines, and suppression of airway inflammation.
Inhaled: 400-800 mcg/day in 2 divided doses for asthma; oral controlled ileal release: 9 mg once daily for Crohn's disease; intranasal: 256 mcg/day in 2 sprays per nostril once daily for allergic rhinitis.
200-800 mcg twice daily via inhalation. Maximum 1600 mcg/day.
None Documented
None Documented
Clinical Note
moderateBudesonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Gatifloxacin."
Clinical Note
moderateBudesonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Rosoxacin."
Clinical Note
moderateBudesonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Levofloxacin."
Clinical Note
moderateBudesonide + Trovafloxacin
2-3.6 hours (terminal elimination half-life); due to high hepatic clearance, systemic half-life is short, limiting systemic exposure.
Terminal elimination half-life is 2-3 hours in adults, reflecting rapid clearance. Clinical context: duration of anti-inflammatory effect may exceed half-life due to receptor binding.
Primarily hepatic metabolism via CYP3A4; metabolites excreted in feces (~60%) and urine (~10-15%). Renal excretion of unchanged drug is negligible (<2%).
Primarily hepatic metabolism via CYP3A4; metabolites are excreted in urine (~60%) and feces (~40%). Less than 10% of unchanged drug is recovered in urine.
Category A/B
Category A/B
Inhaled Corticosteroid
Inhaled Corticosteroid
"The risk or severity of adverse effects can be increased when Budesonide is combined with Trovafloxacin."